[EN] BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT<br/>[FR] DÉRIVÉS BENZIMIDAZOLE EN TANT QUE BLOQUEURS SÉLECTIFS DU COURANT DE SODIUM PERSISTANT
申请人:ALLERGAN INC
公开号:WO2013101926A1
公开(公告)日:2013-07-04
The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said compound, wherein variables R, R1, R2, R3, R4, R5, m, and n in Formula (I) are as defined herein.
[EN] SELECTIVE NR2B ANTAGONISTS<br/>[FR] ANTAGONISTES SÉLECTIFS DU NR2B
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2013049119A1
公开(公告)日:2013-04-04
The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
Condensed 5-membered heterocyclic compounds, processes for preparing
申请人:Dr. Karl Thomae GmbH
公开号:US05434150A1
公开(公告)日:1995-07-18
The invention relates to cyclic imino derivatives of general formula ##STR1## wherein A to G, R.sub.1, Z.sub.1 to Z.sub.6, X and Y are defined as in claim 1, the tautomers, stereoisomers and mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, preferably aggregation-inhibiting properties, pharmaceutical compositions which contain these compounds and processes for preparing them.
BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
申请人:Allergan, Inc.
公开号:US20130172342A1
公开(公告)日:2013-07-04
The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula I
or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said compound, wherein variables R, R
1
, R
2
, R
3
, R
4
, R
5
, m, and n in Formula I are as defined herein.